Clinical Trials Logo

Clinical Trial Summary

The incidence of acute kidney injury (AKI) postoperatively has been identified to be 21.6% in adults and 18.3% in hospitalized individuals. Surgery-related AKI is a severe complication that is related not only to short-term complications as increases in mortality rate and development of cardiac complications but also with complications on long term, such as development of chronic kidney disease. A better understanding of the mechanism of this hypthesis will lead to better management of this complication.


Clinical Trial Description

A randomized blinded prospective study included 206patients who the candidate for major surgery at South Egypt Cancer Institute, Assiut University, Assiut, Egypt. From April 2018 till April 2019, a detailed history and careful examination, routine laboratory investigations were done, Baseline ECG was recorded 24hours before surgery and 48hours postoperative at ICU. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05068167
Study type Observational
Source South Egypt Cancer Institute
Contact
Status Completed
Phase
Start date March 1, 2019
Completion date September 30, 2020

See also
  Status Clinical Trial Phase
Completed NCT03941483 - Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury (AKI) Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery Phase 2
Completed NCT02733328 - Assessment of Plasma and NGAL for the Early Prediction of Acute Kidney Injury After Cardiac Surgery in Adults Study
Completed NCT04829916 - A Study to Evaluate RMC-035 in Subjects Undergoing Cardiac Surgery Phase 1
Completed NCT04165369 - Observational Study to Evaluate the Epidemiology of Surgical-induced Acute Kidney Injury
Terminated NCT02620761 - Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants Phase 2/Phase 3
Recruiting NCT05264285 - Mitochondrial Health and Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients
Recruiting NCT05399537 - Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT Phase 3